BiTE Amgen：BiTE® Technology 101
BiTE® Technology 101
BiTE® Molecule
https://www.amgenoncology.com
The BiTE® immuno-oncology platform offers versatility to potentially target any tumor-associated antigen. The BiTE® platform is being studied across a wide ...
BiTE® Molecule
https://www.amgen.com
A BiTE® antibody construct is a type of fusion protein that is designed to harness the power of the immune system to treat cancer.
BiTE® Immuno
https://www.amgenoncology.com
Amgen is pioneering BiTE® technology to advance the immuno-oncology field and bring new therapeutic approaches to patients. Features of the BiTE® platform.
HLE BiTE® Molecule
https://www.amgenoncology.com
Canonical BiTE® molecules are relatively small recombinant proteins that can be eliminated by the kidneys and have a serum half-life of a few hours. Currently, ...
BiTE Interactive
https://www.amgenoncology.com
BiTE® immuno-oncology technology is designed to overcome these evasive mechanisms by binding directly to surface antigens on the targeted cancer cell.
BiTE the Engager™
https://www.amgenoncology.com
The growing BiTE® immuno-oncology pipeline9. *HLE BiTE® Platform. AMGEN IS. COMMITTED TO. BRINGING T-CELL. INNOVATION TO. PATIENTS. Acapatamab (AMG 160)*. PSMA.
BiTE the Engager
https://www.amgenoncology.com
• Pioneered by Amgen, who continues to accelerate the investigation of BiTE® technology with the goal of enhancing patient experience and therapeutic ...
T 細胞銜接有何魅力？ MSD 攜手Janux！Roche
https://geneonline.news
Amgen 透過銜接2 種抗體的標靶區域來創建這些雙特異性分子BiTE。該分子的一個臂被設計為與細胞毒性T 細胞表面上發現的蛋白質結合，另一臂被設計為與主要在 ...